- Home
- ARCT vs EYPT Comparison
ARCT vs EYPT Comparison
Compare ARCT & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARCT | EYPT |
|---|---|---|
| Founded | 2013 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 163.4M | 419.9M |
| IPO Year | 2019 | 2005 |
Fundamental Metrics
Financial Performance| Metric | ARCT | EYPT |
|---|---|---|
| Price | $17.63 | $3.92 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 5 |
| Target Price | $24.11 | ★ $31.80 |
| AVG Volume (30 Days) | 1.4M | ★ 3.9M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.00 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $82,031,000.00 | $7,539,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.77 | $3,115.57 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.50 | $3.95 |
| 52 Week High | $24.14 | $19.11 |
Technical Indicators
Market Signals| Indicator | ARCT | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 25.99 |
| Support Level | N/A | N/A |
| Resistance Level | N/A | $18.99 |
| Average True Range (ATR) | 0.00 | 0.31 |
| MACD | 0.00 | 0.18 |
| Stochastic Oscillator | 0.00 | 4.71 |
Price Performance
Historical ComparisonAbout ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.